Freya Pharma Solutions Announces Launch of Phase II Clinical Dose-Response Study testing its LybridoTM Concept Targeting Female Sexual Dysfunction
www.freyapharmasolutions.com Study evaluates Lybrido(TM)'s Dual-Action therapy for Female Sexual Dysfunction Innovative clitoral blood flow measurement technique aims to objectively quantify treatment efficacy of two dose-combinations ALETTA Pivotal Study prepared for Late 2025 launch in Europe amid significant unmet medical need Amsterdam, the Netherlands, 4 August 2025 – Freya Pharma Solutions, a pharmaceutical company specializing in […]